Back to results
US 11,896,588 B2Granted
Ophthalmic composition
AssigneeSydnexis, Inc.
InventorsGregory I. Ostrow, Kenneth J. Widder, David S. Baker
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeSydnexis, Inc.
InventorsGregory I. Ostrow, Kenneth J. Widder, David S. Baker
Estimating the term…
Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, Wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
A stabilized ophthalmic composition for treating pre-myopia, myopia, or progression of myopia, comprising from about 0,001 wt % to about 0.05 wt % of atropine or atropine sulfate and deuterated water, wherein the stabilized ophthalmic composition further comprises a buffering agent at a pD from about 4.2 to about 7.9, wherein the buffering agent comprises a citrate buffering agent, an acetate buffering agent, or a combination thereof.
A stabilized ophthalmic composition for treating pre-myopia, myopia, or progression of myopia, comprising from about 0,001 wt % to about 0.05 wt % of atropine or atropine sulfate and deuterated water, wherein the stabilized ophthalmic composition further comprises a buffering agent at a pD from about 4.2 to about 7.9, wherein the buffering agent consists essentially of citrate buffering agent, an acetate buffering agent, or a combination thereof.
Dependencies are inferred from the claim text.